PL3310340T3 - Formulacje o wysokim stężeniu - Google Patents
Formulacje o wysokim stężeniuInfo
- Publication number
- PL3310340T3 PL3310340T3 PL16733703.9T PL16733703T PL3310340T3 PL 3310340 T3 PL3310340 T3 PL 3310340T3 PL 16733703 T PL16733703 T PL 16733703T PL 3310340 T3 PL3310340 T3 PL 3310340T3
- Authority
- PL
- Poland
- Prior art keywords
- high concentration
- concentration formulations
- formulations
- concentration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562182988P | 2015-06-22 | 2015-06-22 | |
| EP15173860.6A EP3108879A1 (en) | 2015-06-25 | 2015-06-25 | High concentration formulation |
| PCT/IB2016/053662 WO2016207778A1 (en) | 2015-06-22 | 2016-06-20 | High concentration formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3310340T3 true PL3310340T3 (pl) | 2026-02-16 |
Family
ID=53491322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16733703.9T PL3310340T3 (pl) | 2015-06-22 | 2016-06-20 | Formulacje o wysokim stężeniu |
Country Status (22)
| Country | Link |
|---|---|
| US (6) | US10603327B2 (pl) |
| EP (3) | EP3108879A1 (pl) |
| JP (4) | JP6916744B2 (pl) |
| KR (1) | KR102636936B1 (pl) |
| CN (1) | CN107979999B (pl) |
| AU (1) | AU2016284935B2 (pl) |
| BR (1) | BR112017027721A2 (pl) |
| CA (1) | CA2987701C (pl) |
| DK (1) | DK3310340T3 (pl) |
| ES (1) | ES3056907T3 (pl) |
| FI (1) | FI3310340T3 (pl) |
| HR (1) | HRP20251498T1 (pl) |
| LT (1) | LT3310340T (pl) |
| MX (1) | MX391040B (pl) |
| PL (1) | PL3310340T3 (pl) |
| PT (1) | PT3310340T (pl) |
| RS (1) | RS67597B1 (pl) |
| RU (1) | RU2731564C2 (pl) |
| SI (1) | SI3310340T1 (pl) |
| SM (1) | SMT202600032T1 (pl) |
| WO (1) | WO2016207778A1 (pl) |
| ZA (1) | ZA201708173B (pl) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20071616A1 (it) | 2007-08-03 | 2009-02-04 | Cosmo Spa | Processo enzimatico per l'ottenimento di 17-alfa monoesteri del cortexolone e/o suoi 9,11-deidroderivati. |
| EP3108879A1 (en) | 2015-06-25 | 2016-12-28 | Cassiopea S.p.A. | High concentration formulation |
| CN115068423A (zh) * | 2021-03-12 | 2022-09-20 | 浙江万晟药业有限公司 | 一种克拉司酮泡沫剂及其制备方法 |
| CN113425845B (zh) * | 2021-08-10 | 2022-12-02 | 成都倍特药业股份有限公司 | 一种预防和/或治疗脱发症的传递体制剂及其制备方法和用途 |
| JP2026513960A (ja) * | 2023-04-07 | 2026-05-01 | アンプリフィカ・ホールディングス・グループ・インコーポレーテッド | アンドロゲン性脱毛症の治療のための組成物及び方法 |
| TW202444338A (zh) | 2023-04-07 | 2024-11-16 | 義大利商卡斯歐皮亞股份公司 | 克拉司酮與米諾地爾之組合療法 |
| CN121969376A (zh) | 2023-09-26 | 2026-05-01 | 卡斯欧皮亚公司 | 用于治疗痤疮样皮疹的皮甾酮-17α-丙酸酯 |
| EP4529925A1 (en) | 2023-09-26 | 2025-04-02 | Cassiopea S.p.A. | Cortexolone-17-alpha- propionate for treating acneiform eruptions |
| WO2025094021A1 (en) * | 2023-10-31 | 2025-05-08 | Lupin Limited | Stable topical cream formulation of clascoterone |
| AU2024399617A1 (en) | 2023-12-14 | 2026-06-25 | Cassiopea S.P.A. | Cortexolone-17αlpha-propionate combinations for treating acne |
| US20250213594A1 (en) * | 2023-12-27 | 2025-07-03 | Inventage Lab Inc. | Novel long-acting injectable composition for preventing or treating androgenetic alopecia containing finasteride |
| WO2025172818A1 (en) | 2024-02-14 | 2025-08-21 | Cassiopea S.P.A. | Pyrilutamide combination therapy |
| WO2026057588A1 (en) | 2024-09-10 | 2026-03-19 | Cassiopea S.P.A. | Clascoterone and minoxidil combination therapy for use in treating hair loss |
| WO2026087531A1 (en) | 2024-10-22 | 2026-04-30 | Cassiopea S.P.A. | Clascoterone formulations and methods of use thereof |
| CN122031486A (zh) * | 2024-11-15 | 2026-05-15 | 南京毓浠医药技术有限公司 | 一种雄激素受体抑制剂的组合物 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB791771A (en) | 1954-07-29 | 1958-03-12 | Merck & Co Inc | Steroid compounds |
| US2985650A (en) | 1958-05-28 | 1961-05-23 | Syntex Sa | 6alpha-ammonio-derivatives of 11-keto cortical hormones |
| CH429716A (de) | 1961-06-24 | 1967-02-15 | Vismara Francesco Spa | Verfahren zur Herstellung von 17a-Acyloxy-21-hydroxy-Steroiden |
| NL6605515A (pl) | 1966-04-25 | 1967-10-26 | ||
| NL6605514A (pl) | 1966-04-25 | 1967-10-26 | ||
| US3780177A (en) | 1967-06-16 | 1973-12-18 | Warner Lambert Co | 17-butyrate,21-ester derivatives of 6alpha,9alpha-difluoroprednisolone,compositions and use |
| US3733318A (en) | 1972-03-23 | 1973-05-15 | Syntex Corp | 21-orthoesters of cortical steroids and methods of preparing same |
| JPS5910799B2 (ja) | 1975-07-15 | 1984-03-12 | 大正製薬株式会社 | プレグナン系ステロイド １７−エステル類の製法 |
| DE3243482A1 (de) | 1982-11-22 | 1984-05-24 | Schering AG, 1000 Berlin und 4709 Bergkamen | Neue 6(alpha)-methylkortikoide, ihre herstellung und verwendung |
| DE3402330A1 (de) | 1984-01-20 | 1985-07-25 | Schering AG, 1000 Berlin und 4709 Bergkamen | 1(alpha),2(alpha)-methylen-6-methylen- und 6(alpha)-methyl-pregnene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate |
| US4920216A (en) | 1987-05-28 | 1990-04-24 | The Trustees Of Columbia In The City Of New York | Selective chlorination of steroids and other substrates directed by covalently linked pyridine derivatives acting as templates |
| US5264428A (en) | 1990-02-16 | 1993-11-23 | Kanoldt Arzneimittel Gmbh | Use of stigmasta-4-en-3-one in the treatment of androgen dependent diseases |
| DE19653730C2 (de) | 1996-12-11 | 1999-06-24 | Schering Ag | Immobilisierte Proteine aus Rohextrakt und deren Verwendung zur Umsetzung von Estern |
| CN1090180C (zh) | 1997-06-25 | 2002-09-04 | 帝人株式会社 | 维生素d3衍生物及其用于炎性呼吸道疾病的治疗剂 |
| US6284234B1 (en) | 1998-08-04 | 2001-09-04 | Johnson & Johnson Consumer Companies, Inc. | Topical delivery systems for active agents |
| DE60209704T2 (de) | 2001-05-22 | 2006-11-16 | Pfizer Products Inc., Groton | Neue kristallforme von azithromycin |
| ITMI20011762A1 (it) | 2001-08-10 | 2003-02-10 | Cosmo Spa | Esteri di 17alfa,21-diidrossipregnene, loro uso come agenti anti-androgenetici e procedimenti per la loro preparazione |
| WO2004060347A2 (en) | 2002-09-03 | 2004-07-22 | Transform Pharmaceuticals, Inc. | Pharmaceutical propylene glycol solvate compositions |
| TW200305396A (en) | 2002-03-27 | 2003-11-01 | Shionogi & Co | Cartilage extracellular matrix degradation |
| ATE338763T1 (de) | 2002-08-02 | 2006-09-15 | Schering Ag | Progesteronrezeptormodulatoren mit erhöhter antigonadotroper aktivität für die weibliche fertilitätskontrolle und hormonersatztherapie |
| DE10236405A1 (de) | 2002-08-02 | 2004-02-19 | Schering Ag | Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie |
| WO2004019953A1 (en) | 2002-08-28 | 2004-03-11 | Hollis-Eden Pharmaceuticals, Inc. | Therapeutic treatment methods |
| DE602004021238D1 (de) | 2003-03-05 | 2009-07-09 | Merck Frosst Company | Stickstoffmonoxid freisetzende prodrugs von diaryl-2-(5h)-furanonen als inhibitoren von cyclooxygenase-2 |
| US20050008704A1 (en) * | 2003-07-11 | 2005-01-13 | Ray Anup Kumar | Pharmaceutical composition for solubility enhancement of hydrophobic drugs |
| EA009902B1 (ru) * | 2004-02-13 | 2008-04-28 | УОРНЕР-ЛАМБЕРТ КОМПАНИ Эл-Эл-Си | Модуляторы рецепторов андрогенов |
| CA2562801C (en) | 2004-04-14 | 2010-09-07 | Eun-Joo Lee | Pharmaceutical composition for treating hair loss and benign prostatic hyperplasia |
| US20060210515A1 (en) | 2005-03-18 | 2006-09-21 | Mower Thomas E | Hair growth formula |
| JP2008189549A (ja) | 2005-05-12 | 2008-08-21 | Astellas Pharma Inc | カルボン酸誘導体またはその塩 |
| PE20070343A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Inhibidores macrociclicos del virus de la hepatitis c |
| ITMI20051695A1 (it) | 2005-09-14 | 2007-03-15 | Cosmo Spa | Uso di 17a-esteri c3-c10 del 9,11-deidrocortexolone cme agenti anti-gonadotropinici |
| FR2893845B1 (fr) | 2005-11-30 | 2010-10-29 | Galderma Sa | Composition sous forme de spray comprenant un corticoide et une phase huileuse |
| AU2014233577B2 (en) * | 2007-08-03 | 2016-03-03 | Cassiopea S.P.A. | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
| ITMI20071616A1 (it) | 2007-08-03 | 2009-02-04 | Cosmo Spa | Processo enzimatico per l'ottenimento di 17-alfa monoesteri del cortexolone e/o suoi 9,11-deidroderivati. |
| WO2011029392A1 (en) * | 2009-09-10 | 2011-03-17 | Youzhi Tong | Androgen receptor antagonists and uses thereof |
| AU2010302350B2 (en) | 2009-10-02 | 2015-06-18 | Journey Medical Corporation | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
| WO2012065065A1 (en) | 2010-11-12 | 2012-05-18 | Follica, Inc. | Methods and compositions for modulating hair growth, wound healing and scar revision |
| JP2014500275A (ja) | 2010-12-06 | 2014-01-09 | フォリカ，インコーポレイテッド | 禿頭症を治療するため、および毛髪の成長を促進するための方法 |
| MX2011008984A (es) | 2011-08-25 | 2013-02-25 | Genomma Lab Internacional S A B De C V | Composicion para la administracion percutanea de compuestos activos que aseguran un tratamiento adecuado para la alopecia androgenetica. |
| CN104334177A (zh) * | 2011-11-25 | 2015-02-04 | 阿德里安娜·贾内尔·杰克逊 | 用于增加毛发生长和/或预防毛发损失的油组合物和方法 |
| US9433268B2 (en) | 2013-03-12 | 2016-09-06 | Mark J. S. Ma | Umbrella having a pivot joint to provide additional degrees of freedom of orientation of its canopy |
| EP2968093A1 (en) * | 2013-03-14 | 2016-01-20 | Allergan, Inc. | Topical compositions comprising bimatoprost and methods for stimulating hair growth therewith |
| ITMI20132157A1 (it) | 2013-12-20 | 2015-06-21 | Cosmo Dermatos Srl | Cortexolone 17alfa-propionate for use in the treatment of skin wounds and/or atrophic skin disorders . cortexolone 17alfa-propionato per uso nel trattamento delle ferite della pelle e/o disordini atrofici della pelle. |
| US9675537B2 (en) | 2014-06-30 | 2017-06-13 | Johnson & Johnson Consumer Inc. | Hair growth composition and method |
| EP3006453A1 (en) | 2014-10-08 | 2016-04-13 | Cosmo Technologies Ltd. | 17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors |
| EP3108879A1 (en) | 2015-06-25 | 2016-12-28 | Cassiopea S.p.A. | High concentration formulation |
-
2015
- 2015-06-25 EP EP15173860.6A patent/EP3108879A1/en not_active Ceased
-
2016
- 2016-06-20 SI SI201631931T patent/SI3310340T1/sl unknown
- 2016-06-20 ES ES16733703T patent/ES3056907T3/es active Active
- 2016-06-20 EP EP25205438.2A patent/EP4650000A3/en active Pending
- 2016-06-20 RS RS20251234A patent/RS67597B1/sr unknown
- 2016-06-20 BR BR112017027721A patent/BR112017027721A2/pt not_active Application Discontinuation
- 2016-06-20 LT LTEPPCT/IB2016/053662T patent/LT3310340T/lt unknown
- 2016-06-20 SM SM20260032T patent/SMT202600032T1/it unknown
- 2016-06-20 FI FIEP16733703.9T patent/FI3310340T3/fi active
- 2016-06-20 JP JP2017566315A patent/JP6916744B2/ja active Active
- 2016-06-20 KR KR1020187001619A patent/KR102636936B1/ko active Active
- 2016-06-20 CN CN201680036665.5A patent/CN107979999B/zh active Active
- 2016-06-20 HR HRP20251498TT patent/HRP20251498T1/hr unknown
- 2016-06-20 PL PL16733703.9T patent/PL3310340T3/pl unknown
- 2016-06-20 EP EP16733703.9A patent/EP3310340B1/en active Active
- 2016-06-20 PT PT167337039T patent/PT3310340T/pt unknown
- 2016-06-20 MX MX2017017119A patent/MX391040B/es unknown
- 2016-06-20 RU RU2018101870A patent/RU2731564C2/ru active
- 2016-06-20 US US15/738,151 patent/US10603327B2/en active Active
- 2016-06-20 CA CA2987701A patent/CA2987701C/en active Active
- 2016-06-20 WO PCT/IB2016/053662 patent/WO2016207778A1/en not_active Ceased
- 2016-06-20 DK DK16733703.9T patent/DK3310340T3/da active
- 2016-06-20 AU AU2016284935A patent/AU2016284935B2/en active Active
-
2017
- 2017-11-30 ZA ZA2017/08173A patent/ZA201708173B/en unknown
-
2019
- 2019-05-01 US US16/400,262 patent/US20190282589A1/en not_active Abandoned
- 2019-08-01 US US16/529,214 patent/US10980819B2/en active Active
-
2020
- 2020-03-24 US US16/828,727 patent/US11213531B2/en active Active
-
2021
- 2021-07-16 JP JP2021117906A patent/JP7196247B2/ja active Active
- 2021-11-23 US US17/456,218 patent/US11883415B2/en active Active
-
2022
- 2022-12-14 JP JP2022199305A patent/JP7458464B2/ja active Active
-
2023
- 2023-12-14 US US18/539,531 patent/US20240189324A1/en active Pending
-
2024
- 2024-03-18 JP JP2024042141A patent/JP2024069534A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO2025003I1 (no) | Fidanacogene elaparvovec | |
| EP3337502A4 (en) | STABLE ANTI-IFNAR1 FORMULATION | |
| DK3283625T3 (da) | Nukleasemedieret genomeditering | |
| PL4070788T3 (pl) | Formulacje farmaceutyczne | |
| SI3310340T1 (sl) | Formulacija visoke koncentracije | |
| EP3339331A4 (en) | COMPOSITION | |
| EP3398996A4 (en) | COMPOSITION | |
| DK3331529T3 (da) | Muskarinagonister | |
| EP3345473A4 (en) | HARVESTER | |
| DK3253485T3 (da) | No-holdige sammensætninger | |
| DK3394281T3 (da) | Gærcelle | |
| EP3364945C0 (en) | SOLID FORMULATION | |
| EP3381654A4 (en) | Liquid blow molding method | |
| EP3383912A4 (en) | TOPICAL FORMULATIONS | |
| EP3351087A4 (en) | HARVESTER | |
| DK3296597T3 (da) | Krydshovedmotor | |
| EP3395887C0 (en) | FLUOROR RUBBER COMPOSITION | |
| DK3322295T3 (da) | Sammensætning | |
| EP3390240A4 (en) | LOADING STRUCTURE | |
| EP3548009A4 (en) | POLYMANANOPARTICLE | |
| EP3272204A4 (en) | HARVESTER | |
| DK3316856T3 (da) | Blandede formuleringer | |
| DK3280447T3 (da) | Farmaceutiske formuleringer | |
| DK3173071T4 (da) | Maropitantformulering | |
| DK3393254T3 (da) | Sammensætning |